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Abstract
Introduction: Controversies still exists within the research fraternity on the form and level of incentives,
compensation and reimbursement to study participants in resource-constrained settings. While most research
activities contribute significantly to advancement of mankind, little has been considered in rewarding directly the
research participants from resource-constrained areas.
Methods: A study was conducted in Zimbabwe to investigate views and expectations of various stakeholders on
study participation incentives, compensation and reimbursement issues. Data was collected using various methods
including a survey of about 1,008 parents/guardians of school children participating in various immunological cohort
studies and parasitology surveys. Community advisory boards (CABs) at 9 of the sites were also consulted. Further,
information was gathered during discussions held at a basic research ethics training workshop. The workshop had 45
participants that including 40 seasoned Zimbabwean researchers and 5 international research collaborators.
Results: About 90% (907) of the study participants and guardians expected compensation of reasonable value, in
view of the researchers’ value and comparison to other sites regardless of economic status of the community.
During discussion with researchers at a basic ethics training workshop, about 80% (32) believed that decisions on
level of compensation should be determined by the local research ethics committees. While, the few international
research collaborators were of the opinion that compensation should be in accordance with local guidelines, and
incentives should be in line with funding. Both the CAB members and study participants expressed that there
should be a clear distinction between study incentive and compensation accorded to individual and community
expectations on benefits from studies. However, CABs expressed that their suggestions on incentives and
compensation are often moderated by the regulatory authorities who cite fear of unknown concerns.
Conclusion: Overall, both personal and community benefits need to be considered colectively in future studies to
be conducted in resource-constrained communities. There is projected fear that recruitment in future may be a
challenge, now that almost every community, has somehow been reached and participated in some form of
studies. A major concern on reimbursement, compensation or incentives should be internationally pegged
regardless of different economic status of the individuals or communities where the study is to be conducted.
Background
Biomedical studies are well known to add scientific solu-
tions to problems bedeviling mankind, animals and their
environment [1-3]. Through conducting research activ-
ities, some benefits are also realized by individuals and
communities worldwide. Research programs assist in
finding out new ways for treatment, to solve some medi-
cal problems and to improve the health standards of liv-
ing for humans [4]. However, with the benefits realized at
multiple-levels, concern is raised where the subjects of
the research activities, who are at the core of the pro-
gramme, rarely obtain any visible individual benefits [5].
Research participants indulge in different study protocols
for different reasons. Sometimes the main driving force is
beyond the participants’ control [6]. While currently, the
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international research foundations and organizations are
struggling to rationalize participation, in an effort to tame
the research jungle [7,8]. However, at individual levels
there are a couple of questions that go unanswered for the
participants who are right at the bottom of the planning
and the research protocol hierarchy [5,6]. Some of the per-
tinent questions by the research participants that go unan-
swered include the following: i). What is my immediate
benefit? ii). Who will benefit from this work being con-
ducted? ii). Why are these people (researchers) using all
the resources in my community and yet we have so many
other problems? iii). Why my community and not that
other community? iv). The researchers are here for only
2 years, then what next? v). These people are well off, bet-
ter than anyone in our community, so they must be bene-
fiting from the activities?
While researchers are well aware of the main goal(s)
including on how to achieve these through data/sample
gathering, a lot need to be understood on the study parti-
cipants and their feelings. Further, it is reasonable not to
assume but to become part of the community and feel
from within what the participants expect from taking
part in studies and providing their biological specimens.
Some progress has been achieved along these lines with
moderate consideration on certain aspects that affect
study participants in the form of repayment or reimbur-
sement, which is replacement of what could have been
lost or what could have been gained during the time the
participant is involved in the research activities [9-13].
While there are other forms that have been coined into
studies that include giving out incentives; that represents
something that motivates or encourages participation.
Incentives are rarely permitted by study regulators for
reason still unclear to many researchers, especially when
an incentive is considered as payment or a concession to
stimulate greater participation, this is regularly not per-
mitted by most in-country study regulatory agents and in
certain instances by research groups [5]. Where the com-
monly applied consideration of benefits to study partici-
pation by researchers is compensation, representing
something that makes up for an undesirable or unwel-
come state of affair or this can be something, typically
money awarded to someone as a recompense for loss,
injury or suffering.
Most research activities involve an intertwined relation-
ship between different players working together to achieve
a common goal. In the case of simple investigative research
emanating from a researcher, there are several regulatory
authorities that may be responsible for giving approval for
sample shipping or exchange, drug use and other com-
monly regulated activities [14]. Additionally, there could be
some local authorities that are responsible for over sight
within certain areas and research institutions. Key to the
regulatory and monitoring biomedical research involving
humans is the ministry of health and other ministries that
deal with the public. In certain locations, there is political
leadership that has control over access and running any
research activities in their communities [5]. The biomedical
researcher/investigator has to prepare documents that go
through all the required local regulatory institutions and
offices that include the ethics review board. The ethics
review committees are believed to be representing the
communities where research is to be conducted. The
members are believed or expected to have the community
at heart and to also have in-depth understanding of both
traditional and cultural beliefs. In this hierarchy, the
research community/participants are located right at
the bottom or the receiving end. The concerns of the com-
munity or participants are assumed as represented by
the structures within the areas and the regulatory authori-
ties [5,14].
Controverses exists on the forms and levels of incentive,
compensation and to lesser extent re-imbursement to
study participants in resource-constrained settings.
Inequity exists on addressing study participants’ involve-
ment in research studies according to economic status of
the areas where the studies are conducted. Regulatory
authorities need to reach a compromise, rather than dic-
tate the level, type or amount. Currently, there is a huge
demand for biomedical research or trial populations, espe-
cially in areas still developing and carrying the burden of
diseases. Africa has abundant virgin testing grounds for
new tools produced by biomedical and genomic revolu-
tion, and vaccines for several infections challenges. This is
compelled by the great diseases burden with easy to reach
sample size. Rarely are requests for conducting studies in
the African populations denied due to the scarce and poor
health facilities, hence communities and the leaders would
be expecting access to some improved health tools and
products through hosting of studies. In such areas where
capacity is lacking, the biomedical research activities being
conducted may seldom be observed and monitored closely
by the regulatory authorities and even by CABs who may
not understand the scientific implications of such studies.
The participant is found to be lowly considered and rarely
consulted during the design of the study protocols rather
everything is assumed from consultations with ministries
and regulatory authorities. Major concern is that the com-
munity settlements are often dispersed and individuals
find it difficulty to have a common stand. While in recent
years it has come to light that some sponsors/funders are
ready to accommodate as long as proposed in the line of
expenditure by the investigating team towards study parti-
cipant incentives, reimbursement and even compensation,
since the sponsors sometimes have commitment to the
community by providing services including alleviating
poverty. The whole stages of considering compensation or
even rewarding study participants has never been
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appropriately debated taking into account the concerns of
the communities. While application of ethical principles
has no mathematical formula, this has to take into account
various prevailing factors that include economic, social,
cultural religious, civil protection systems and other rele-
vant factors. These factors may lead to procedural differ-
ences, but the spirit of the principle remains the same.
Some unscrupulous international and local researchers
take advantage of the poor and uncoordinated research
systems in resource-constrained areas. Rarely would local
authorities keep keen track of the activities, and such a
system is bound for abuse. Further, due to rampant pov-
erty coupled with ignorance (in a sense), and sometimes
there is prevailing abundant human rights abuses; this
entail disregard of community rights and respect [15-18].
Most research activities require monitoring and this deci-
sion must be reached at planning level in comparison to
studies conducted in other sites in developing countries.
The African health challenges expose research partici-
pants, and also including researchers and institutions to
exploitation, coercion, enticement and inducement
[5,19-22]. Resource constrained communities are generally
deprived of most common attributes of a well-sustained
and democratic societies [23,24]. The basic human rights
are not observed and the individuals, probably through
ignorance or due to none existence, do not have any
recourse to law [23]. This aspect is not available in African
communities and sometimes the poor participant living in
resource-constrained community can get assistance from
NGO who attempt to lobby on their behalf [25,26]. How-
ever, critically analyzing the situation reveals a couple of
stages where such mishap may be avoided during the
planning stages of the proposal. The sponsor/funder,
investigator, regulatory authorities assume not aware of
this infringement on the participants. Through activities in
immunological studies and parasitology surveys conducted
in Zimbabwean communities; a study was conducted to
investigate views and expectations of various stakeholders




Eleven communities from districts in Zimbabwe partici-
pated in the study as follows: Burma Valley, Charehwa in
Mutoko, Magaya and Chigono in Murehwa, Goromonzi,
Kariba, Magunje and Karoi in Hurungwe, Shamva and
Trelawney [27-43]. These rural districts are situated in
areas where communities survive on subsistence farming,
growing maize, groundnuts, sunflowers and soya beans.
While a few of the communities survive on market gar-
dening and small-scale irrigation activities. Data from
1,008 adult participants enrolled in the 11 intervention
communities of biomedical studies were included in this
analysis. The observations in school children involved
about 1,450 school children (95%CI: 120-173 per school)
in 10 rural schools. We excluded individuals who were not
willing to respond to the questionnaire at the baseline data
collection points. Responding to the questionnaire at base-
line indicated willingness to participate even though such
individuals may not have participated at other subsequent
follow-up time points.
Data collection
Data was collected in various methods including a survey.
The survey of parents/guardians of school children parti-
cipating in various immunological cohort and parasitlogy
survey studies. Community advisory boards (CABs)
members at 9 sites in the different study communities
were also consulted and lastly 45 participants that includ-
ing 40 Zimbabwean researchers and 5 international
research collaborators. Community based field health
workers who were part of the community and were also
involved in study promotion and implementation activ-
ities collected data regarding participation. The field
staffs were trained in interviewing and observation tech-
niques, data recording, and participatory community
motivation approaches. The field staff recorded willing
participation indicators during the days of the follow-up
with a structured, observational questionnaire. In addi-
tion, field staff recorded self-reported attendance at the
end of the study follow-up point through a questionnaire.
These were compared to the data recorded by the
research teams at the field site and in the laboratory
shown by the actual presence of the collected biological
sample. In order to arrive at an outcome that describes
willingness to participation, we selected six complemen-
tary survey indicators that measure multiple dimensions
of potential willingness (Table 1). Based on this group
separation, we used characteristics of participation in the
groups to describe them in meaningful, qualitative terms:
Group 1 = ‘willing participants’, Group 2 = ‘moderate
participants’, Group 3 = ‘availability of samples as willing
to participate’ Group 4 encouraged participants, Group
5 = ‘organized participants’ and Group 6 ‘participation
due to self/community benefits.’
Statistical analysis
To identify patterns of study participation, we explored the
quantitative distribution of study participation in terms of
the six quantitative indicators (Table 1). Six differentiated
groups were identified. To confirm the patterns of study
participation we further examined the distribution of the
willingness from samples obtained at examination day and
the availability of samples, including reports from encour-
agement by the CABs as indicators. Willingness to partici-
pate measures in diverse communities and individual level
characteristics were deduced between groups with data
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compared. The identified participation groups were then
used in the comparison analyses. Data were analyzed
using Statistical Package for Social Scientists (SPSS)
version 8.0 for Windows, SPSS Inc. Chicago, USA.
Ethical approval
The biomedical studies obtained ethical approval from the
Medical Research Council of Zimbabwe and also for each
area, local leaderships were consulted and permission
granted [27-43]. The provincial medical and education
directorates provided permission while at the community
level; the community leaders and CABs were first con-
sulted for the main biomedical studies and also accepted
the study. Informed consent was obtained from commu-
nity leaders, adult participants, parents or guardians of
school children prior to implementation of the main bio-
medical projects.
Results
The field-based monitoring staff assessed the biomedical
research compliance during baseline examination and at
each subsequent follow-up time point in different studies
conducted over a period of 6 years, from January 2005 to
December 2010. The median duration of studies was
2 years, range: 0.5 year - 4 years, in 11 community-based
studies, giving a total of 26 time points. At the commu-
nity level, on average there were 95 participants per site
(95% CI: 73 - 117), with participation patterns observed
and a questionnaire administered. A total of 9 commu-
nity advisory boards were interviewed (median 8 mem-
bers/community, 95% CI: 7-12). Five of the studies
involved taking blood samples while the rest involved
epidemiological parasitology surveys and treatment
programmes.
The level of participation varied, depending on the
indicator used and the source of information. The
encouragement by community-based staff (CABs) led to
a moderate increase of 35% from the original 25% in the
different communities. Participation compliance as
observed by the research staff registered an increase
during the follow-up visits where treatment was pro-
vided or a token of appreciation was given, with a med-
ian proportion of 80% (IQR: 65-95) in communities
assessed. After 6 years of intensive research study imple-
mentation, the questionnaire administered by the
research staff assessing study participation recorded 80%
of respondents reported needing personal benefit from
participation, and over 80% explicitly hinting on the
need for revisions in determining the benefits for study
participation. During the last intensive follow-up in each
community the study staff deduced a declining willing-
ness to participate, regardless of such benefits like provi-
sion of treatment for the examined parasite (Figure 1).
By the end of the study, it was revealed that compensa-
tion and incentives were constantly being indicated as
the main stimulation factor for adults’ participation.
Table 2 summarizes the results of the analysis, which
identified six distinct participant groups based on purely
on willingness to participate, and provision of all required
samples as indicators. Group 5 (10 schools assessed), dif-
fered from the other groups with respect to the partici-
pants under observation as a type of a highly organized
community with certain rules and regulation. While indi-
cators 1 and 4 were more of community leaders and
Table 1 Indicators for study participation as classified according to groups and the rational or interpretation for
analyses.
Group Indicator Rational and Interpretation
Study participation indicators
1 “Willing participation” Proportion of attendance during which
samples were collected (as observed by community-based health
staff).
Indicator for the intention to willingly participate. Indirect indicator to
measure contentment and awareness.
2 “Obtaining all required samples” Proportion of samples obtained
during the study (as observed by research staff).
Individuals readily available and provide the required samples.
Considered to be a more reliable indicator for actual attendance than
“willing participation.”
3 “Samples available on incentive days” Proportion of samples
obtained during which an incentive was given out (judgment by
research staff after observing trends of the samples given for each
study visit and at all follow-up visits).
Considered the most reliable indicator for need to be compensated.
Research staff working in the community later administered
questionnaire after the observations of samples available on day
incentives were given out, during the time points compensation was
available and days thereafter the news has filtered out of the
incentive.
4 “Community Advisory Board members persuasion” the occurrence
of samples during and after CABs talking to adult participants.
Indicates behavioral change due to CABs talk/chat. Reflects an
increase or a decrease in number of samples during the period.
5 School children participation
“Provision of blood samples” Present at school and availability of
blood sample on the day bleeding is conducted.
Identifies school children providing any other none invasive samples
during the study follow-up period.
6 “Treatment days” Total number of participants treated during the
day’s treatment was recorded.
Identifies proportion of participants with observed participation
during treatment days.
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research staff noting upsurge of participation from
records of samples obtained. These observations were
noticed to decline with time into the study even though
this recorded a high variability in all of the indicators as
it was difficulty to base participation on the persuasion by
the CABs members. Groups 2, 3 and 6 comprised indica-
tors with the highest visible and tangible outcomes, while
Group 2 with an initially high observation that declined
over time, and group 4 showed a clear pattern when
incentives were made available. Group 6 showed that
regardless of the most important benefit to the partici-
pants of treatment available at no cost, participation was
seen to decline drastically with time into the projected
timeframe, an indication of probable participation fatigue.
Table 2, shows the difference between groups in 6 differ-
ent participation indicators (research staff-reported, com-
munity observed) and two other monitoring indicators.
Table 2, summarizes the need for compensation, incen-
tives or re-imbursement through active participation at
community level, through passive discussions with
researchers and regulatory agents and at different
institutions. Since the assessment/observation was stan-
dardized at community levels there is no difference
between the six groups regarding features such as
‘Number of follow-up events per community’, ‘Average
number of participants per event and community’, and
‘Number of participation during the baseline and subse-
quently at each follow-up time point’. However, groups
differed significantly regarding active participation at the
events. School children in organized settings emerging to
show high participation at all times at above 80% and
70% participation for parasitology/blood sampling and to
receive treatment, respectively. The level of participation
at school events was similar across groups, since partici-
pation was mandatory for school children in all schools
in the study site (Table 2).
Participation group indicators correlated with each
other and the estimates indicate that ‘Total number of
compliance by at least one indicator group’ was positively
associated with availability of samples of each group
(Table 1). The results showed that availability of personal
incentive, compensation or re-imbursement were more
Figure 1 Showing the trends in levels of participation according to groups used in the analysis at different follow-up time points for
the study sites summarized. The time points for each group may differ in year and type of study but the measurement was similar of the
research subject willingness to participate.
Table 2 Level of attendance or provision of samples (%) at study sites for school children and adults relative to


















12.4 (8 - 17)
54.8% (795)
1,008
38.8 (18 - 63)
60% (605)
1,008 1,008 1,008 1,008 1,450
Provided samples: Urine/feaces % 80 25 35 70 70 80 80
Provided blood samples % 80 45 45 80 80 80 80
Received treatment 70 45 35 80 80 80 80
Received parasitology results % 35 25 35 80 80 80 80
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likely to enhance participation (OR: 3.38; 95% CI: 1.07-
7.70) and to access any form of token given by research-
ers in community (OR: 2.02; 95% CI: 1.44-3.82). Further-
more, even school children from religious sector that do
not take treatment was positively associated with increased
participation when there is an incentive or a small token
(provision of sweets or school writing notebooks) of
appreciation (OR: 2.18; 95% CI: 1.17-3.20); an increase
from 70% to 80% to receive treatment and a further
increase from 35% to 80% encouraged to know their infec-
tion status when an incentives was introduced (Table 2).
About 90% (907) of the study participants and guardians
expected a reward of reasonable value, in view of the
researchers’ value and in comparison to what is offered at
other sites regardless of economic status of the commu-
nity. Discussion among researchers at a basic ethics train-
ing workshop indicated that 80% (32) believed the
decisions on level of incentive should be determined by
the local research ethics committees (Table 3). While, the
few international research collaborators were of the opi-
nion that reward or compensation should be in accor-
dance with local guidelines, and in line with funding as
agreed and documented in the protocol during the design
and reviews. The study revealed that participants and
guardians were not happy about decision on level and type
of incentive, reimbursement or compensation being
reached on behalf of study participants without consider-
ing their expectations. On considering expectations of
reward revealed that researchers should consult CAB
members since they represent the community. In contrast
to the adult participants and guardians of children
involved in studies, who were of the opinion that compen-
sation and incentives should be at individual level. Both
the CAB members and study participants expressed that
there should be a clear distinction between study incentive
and compensation according to individual and community
benefits from studies. Finally, CAB members expressed
that the regulatory authorities that normally cite concerns
unknown to them, often moderate their suggestions.
Discussion
Realization of ethical principles by study participants in
communities starts with researchers as they draw out
the proposed protocol. These are upheld or authenti-
cated by the ethics committees through reviewers as the
study protocol goes through assessment and the
approvals process. Further, data safety and monitoring
boards (DSMBs) try to observe that ethical guidelines
are maintained and there is no prejudice while testing
the study hypotheses. While the regulatory authorities
(e.g. Medicines Control Authorities, Medical Research
Councils, etc.) verify that ethical principles are adhered
to and practised during the conduct of the studies.
However, governments through the ministry of health
and other ministries overseeing research, sometimes
take advantage of the research activities to fulfil their
own political promises using resources supposed to be
research incentives. Very often it is not rare to find
some policy makers twisting the regulations to achieve
certain goals for the communities. While rarely advo-
cacy groups including NGOs represent the community
leaders and the voiceless participants.
Lack of empowerment exposes African research parti-
cipants and even African researchers and institutions to
exploitation, coercion, enticement and inducement that
would compromise overall voluntariness, and even
upholding fairness is research studies. The sponsor and
the investigator must take every effort to ensure that the
research is responsive to the health needs and priorities
of the population or community in which it is to be car-
ried out. If the capacity is lacking, steps must be taken to
strengthen the oversight mechanisms [4]. Usually, some
key players are easily identified with major responsibil-
ities in research, however, the concern in determining
the respect for the research participant is often over
looked. Most guidelines refer to research participants as
mere study components to be protected disregarding the
need for rewards and individual benefits. The hierarchy
in research authority and all responsible overseers should
understand the demands and needs of the communities
they protect. Research in resource limited areas need to
have prescriptive guidelines that accounts for individual
desires for rewards. The research participant is a living
individual from whom a researcher obtains data and spe-
cimens. The investigation is performed on the research
participant that means the individual is central to the
Table 3 Preference of incentives or compensation given to study participants.
Target respondent Individual award Monetary award Community service or as
development
Study participant n = 1,008 Award (100%) Award (100%) Limited award (<50%)
CABs/Community Leaders n= 73 Limited award (<50%) None Award (100%)
Researchers n = 32 Limited award (<50%) None Award (100%)





Institutional Review Board/ National Regulatory
Authority n = 4
Limited award (<50%) Limited award
(<50%)
Award (100%)
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activities. Researchers and all responsible authorities have
ethical and legal obligations to protect and satisfy human
participants universally [3,13].
The fundamental ethical principle of justice requires
fairness or entitlement that is giving to each what is due.
Human beings are morally equal and should be treated as
such regardless of colour, creed, race or religion including
economic status. This principle of justice demands fairness
in treatment of individuals and communities as such there
should be equitable distribution of the burden and benefits
of research. Important implications for such issues include
rewards to participants during the study and post-study
benefits. Generally, the communities in resource-
constrained areas still do not enjoy the fruits of study par-
ticipation at an individual level. The fundamental principle
of autonomy requires that the wishes and choices of an
individual be respected [2]. Individuals in research studies
must be their own masters and can act or make free
choices and take decisions without constraint of another.
This is rare where no individual opportunity is given to
make an informed decision to ask if not demand for
reward, rather level and the regulatory authorities presume
the type of reward, and very often the principle of divide
and rule is applied. No discussion is permitted even
though consent is obtained. Most resource-constrained
communities do not exercise their demand rights but are
entangled in mob participation that is taken advantage of
by the area regulatory authorities under the pretext of
representing the participants.
Most communities involved in studies or clinical trials
are presumed to understand the essence of research.
Even with these assumptions, participants should be
given adequate information and explanation hence this
implies that they volunteer to be objects of some experi-
ments. Even though being aware that it is not an obliga-
tion to participate in the research, most resource
constrained communities and individuals flow together
without demanding or exercising the right of being free
to refuse participation. The success of research is highly
dependent on the willingness and cooperation of the par-
ticipants during the protocol activities, by providing
information or specimens. Informed consent plays an
important part in this regard [1,2,7]. The responsibilities
often are weighted on the investigator even though there
are considerable responsibilities on the research partici-
pant. In most instances, community representatives are a
major player in decision making in as far as research par-
ticipation. Researchers and trial sponsors need to consult
communities through transparent and meaningful parti-
cipatory process that involve participants during the early
stages in the design, development, implementation and
monitoring of the study activities [18]. Consultations
maybe arranged through local community leaders such
as headmen, chiefs, community health workers and local
civic leaders. Most communities where research activities
have been conducted, certain mechanisms have been
established for community engagement by establishing
community advisory boards.
Researchers or investigators have mammoth responsibil-
ities that include extreme caution on the vulnerable popula-
tions. The Helsinki Declaration mentions the observation
of the benefits to the community [1]. The Investigator must
make evaluation on the benefits to the communities and or
individual. The sponsor or investigator should make every
effort to ensure the work is responsive to the health needs
and the priorities of the population or community in which
the study is being conducted. After the study or interven-
tion, the knowledge generated should be made available for
the benefit of the population or community [1-4,7].
One challenge of assessing the effectiveness of biomedi-
cal field research implementation is the lack of a reliable,
unbiased and accepted indicator to measure participation.
Compliance with the biomedical research programme and
intervention (e.g. epidemiology project, clinical trials or
testing clinical tools) is an important indicator of a suc-
cessful implementation strategy. To our knowledge, none
of the several studies that measured study participation in
relation to compensation and giving out incentives as
effectiveness to improve participation assessed determi-
nants of compliance directly. To date, the most common
end-points used to assess compliance rely on statistics
deducted from successful follow-up as the indirect obser-
vation of willingness to participate and these indicators are
often assessed once, usually at the end of the intervention,
and the reliability of these indicators is unknown. Self-
reported compliance in the context of an interview is
known to produce inflated results due to reporting bias. In
this study we use six measures of direct observation and
researcher tallying attendance from sample availability
to create a score to classify participation according to ‘will-
ingness to participate’ by being present at examination and
interview day, and ‘provision of samples’ as required on
appropriate days. However, this approach to participation
and availability of sample classification uses components
that can readily indicate magnitude of willingness. Agree-
ing to be part of the study forces the investigator to sub-
jectively determine the acceptance of the study by the
community. There is a need for objective methods to clas-
sify participants into distinct willing groups and also to
consider views of the CABs and other community leaders.
In this article we present a detailed analysis of research
study compliance among participants from resource lim-
ited settings who participated in different community
based studies in rural Zimbabwe. The assessment detected
a highly statistically significant demand for incentive in
school children and in adults with an overall compliance
of above 80% based on both community- health worker
assessment and the research staff. Here, we use research
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data collected over a number of studies whose participant
compliance was monitored by CABs and the study
researchers to objectively deduce participation. We then
use the classified groups to describe the participation
determinants that are associated with the general
researcher-participant attitude in resource-constrained
setting.
Systematic reviews of biomedical studies and clinical
interventions in developing countries reveal that majority
of the global inhabitants have somehow been reached by
certain forms of research programme that demand their
participation. Further, from empirical research data, the
world is now becoming a village in as far as being accessed
by study programs is concerned. The global research
events indicate that it is becoming increasingly difficulty to
isolate communities from what was practiced in other
areas during conduct of research programs. Even justifica-
tion for grossly different levels of incentives, compensation
or reimbursement can no longer continue, as the world
becomes a global village. There is need for collective con-
sideration of both personal and community rewards in
future studies to be conducted in resource-constrained
communities. Information available indicates a projected
fear that recruitment in future may be a challenge, now
that almost every community has somehow been reached
and participated in some form of research studies. A
major concern is that study participation rewards should
be internationally pegged regardless of different economic
status of the individuals or communities.
The challenge for incentives, compensation or even
reimbursement is addressed unequally between regions
and development status of the community or country.
Resource constrained communities welcome many
forms of studies regardless of the exploitation levels,
due to poverty. Most of these communities are not
empowered to air out their demands. Further, in such
communities there is no recourse to challenge irrational
health research policies and administrative decisions. If
research intellectual and legal rights can be shared equi-
tably between researchers and their institutions - what is
preventing individualized benefits to study participants?
We characterized six distinct participation groups in stu-
dies conducted over 6 years among participants of
school- and community-based studies in rural Zimbabwe.
Participation characteristics that were most strongly
associated with the categorized groups include giving
incentives, the level of compensation or reward for time
taken to participation. These three forms of study partici-
pant benefit were strongly associated with participation.
Promotion of efforts to give the study participants some-
thing would more easily encourage participation, and
presumably reduce recruitment time.
Our findings suggest that the motivation to provide
samples and to participate; even for treatment requires
some form of rewards. In addition, higher compliance
and obtaining samples was associated with the frequency
of issuing out some token of appreciation to promote
individual attendance at sample collection time point. It
is likely that eager participants providing the biological
samples are more interested in participating at the
related promotional events and with incentives. Apply-
ing the theory and belief of due influence if incentives
are used, has no place in designing studies in the mod-
ern research programme. These coherent findings on
the motivating factors for participation underscore the
importance of determining form and level of incentive
for the participants prior to implementing the project.
In combining objective indicators that measured visible
signs of willing participation (e.g. provision of biological
samples or being present to give the samples especially
blood samples for immunological work) with proxies
indicative of responsive to CABs encouragement and
the presence of the biological samples collected at the
required time point increased the quality of measure-
ment and reduced the potential for reporting bias. The
CABs evaluation on compliance generated much lower
willingness rates than research staff on actual sample
availability observation. This underscores the potential
for bias in situations where community based staff as
members of the CABs evaluate their own work through
compliance after mobilization. Our results highlight the
importance of choosing independent staff and a valid
and responsive indicator to assess willingness and com-
pliance and to draw conclusions about the need or
effectiveness of incentives in intervention programme.
Despite an intensive baseline and continuous mobiliza-
tion campaign carried out by research teams and CABs
members, we observed 35% overall compliance without
any reward given out at subsequent follow-up time point.
However, when incorporating a simple token or reward in
the form of dried fish and cooking oil, participation
increased to over 70%. While during the follow-up when
the rewards were not available, there was a reasonable
response to participation on the first day but when partici-
pant realized that nothing was being given out, the atten-
dance dropped drastically. Introduction of a small token
or reward during follow-up showed an increase to treat-
ment uptake, even when giving out treatment with swee-
tened orange crush juice to a sector of school children
from a religious group that does not accept treatment.
Our findings suggest that biomedical research programme
would benefit from reassessing the core requirement for
compliance. According to information from resourced
communities, there are stark differences in marketing
messages and approaches to reach the critical fraction of
the population to participate in such studies. Our analysis
identified some characteristics associated with increased
willingness to participate, after receiving a small token or
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reward, indicating the potential to draw community mem-
bers to the study. Most of the concerns can be assessed
and addressed during the writing up of the protocols and
incorporated during marketing and promotion strategies
targeting the participants and informing on the personal
benefits and rewards from participation. Based on the
characteristics that we measured, it was clear to differentiate
the willing participant from ‘incentive driven participation
(Table 2). In the study, the population of the participant
groups included the most marginalized rural communities
by observable characteristics: they were poor, lived further
from health services centres, rarely had enough daily
resources, the communities have high prevalence of
neglected tropical diseases. We give evidence of the need to
include individual token of appreciation. But the agents
involved in designing and reviewing the protocols rarely
would agree to reward participants in whatever form that
the communities would appreciate.
In the resource constrained areas context, programme
planning may benefit from assessing easy measurable fac-
tors like the individual desires and community expecta-
tions, a large proportion of population subgroups in these
poor communities that can be targeted for biomedical
research sites do not have excessive demands for compen-
sation or rewards at individual level. Those insights sup-
ported by our data are consistent with recommendations
for a successful rollout of clinical trials programme deriv-
ing from other previous studies. Central government sug-
gested levels of appreciation for the communities are not
in line with what the community and individuals expect
and sometimes rarely would the communities receive
these contributions from the researchers. Normally, it is
not uncommon that resources from research programme
get diverted or replaces government responsibilities, hence
individual senior government officials mat benefit from
such confusion. Individual benefits should be considered
separate from government responsibilities where these are
required. As a result, regulatory authorities very often pro-
pose making use of community rewards from study pro-
gramme for community developments, thereby portraying
differences to studies conducted in resourceful areas. The
difference in not permitting the rewards to an individual is
beyond any reasonable thinking besides among those who
wish to deny these communities their dues from participa-
tion in studies.
There are limitations to this study. The participating
communities were not homogenous regarding preexist-
ing infrastructures, previous exposure to research cam-
paigns and biomedical programme, as well as political
support to participate in the study. Finally, data on the
willing to participate and comparable time points where
a reward was introduced, may somehow differ because
(i) the indicator was implemented by different groups,
and (ii) availability of samples and presence to uptake
treatment in non-invasive biomedical studies. We
believe such measurements somehow enhanced the
reliability of willingness to participate due to a direct
visible benefit and none invasiveness of the study
procedure.
Conclusions
Analyses of implementation effectiveness and the will-
ingness to participate in research programme are rarely
published. Our findings suggest that individuals from
resource-constrained settings are marginalized in decid-
ing their fate and desires for their participation in
research studies. This finding suggests how researchers
could identify from the communities where studies are
to be conducted, the general wish for rewards of the
populations most likely to encourage participation in
studies. Introduction of such rewards would be greatly
beneficial to clinical, epidemiological and other similar
studies by reducing recruitment time frame in reaching
desired sample sizes. The key finding here is that commu-
nities feel marginalized in decision making. There is no
clear conclusion on the view of the stakeholders on parti-
cipation incentives, compensation and re-imbursement.
The subjects need awareness on their rights under the
principles of Universal declarations of Bioethics and
Human Rights and other international normative instru-
ments on life sciences research ethics.
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